Research programme: haematological malignancy therapeutics - Evotec SE/Leukemia & Lymphoma Society
Latest Information Update: 26 Sep 2019
At a glance
- Originator Evotec AG; The Leukemia & Lymphoma Society
- Developer Evotec SE; The Leukemia & Lymphoma Society
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Haematological-malignancies in USA
- 07 Nov 2013 Early research in Haematological malignancies in USA (unspecified route)